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Candidate  gene  and  genome-wide  discovery 
studies  have  identified  a  set  of  novel  disease   
alleles  in  patients  with  myelodysplastic  syn-
dromes (MDSs), acute myeloid leukemia (AML), 
and myeloproliferative neoplasms (MPNs). These 
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Somatic Addition of Sex Combs Like 1 (ASXL1) mutations occur in 10–30% of patients with 
myeloid malignancies, most commonly in myelodysplastic syndromes (MDSs), and are associ-
ated with adverse outcome. Germline ASXL1 mutations occur in patients with Bohring-Opitz 
syndrome. Here, we show that constitutive loss of Asxl1 results in developmental abnormali-
ties, including anophthalmia, microcephaly, cleft palates, and mandibular malformations. In 
contrast, hematopoietic-specific deletion of Asxl1 results in progressive, multilineage cyto-
penias and dysplasia in the context of increased numbers of hematopoietic stem/progenitor 
cells, characteristic features of human MDS. Serial transplantation of Asxl1-null hematopoi-
etic cells results in a lethal myeloid disorder at a shorter latency than primary Asxl1 knockout 
(KO) mice. Asxl1 deletion reduces hematopoietic stem cell self-renewal, which is restored by 
concomitant deletion of Tet2, a gene commonly co-mutated with ASXL1 in MDS patients. 
Moreover, compound Asxl1/Tet2 deletion results in an MDS phenotype with hastened death 
compared with single-gene KO mice. Asxl1 loss results in a global reduction of H3K27 tri-
methylation and dysregulated expression of known regulators of hematopoiesis. RNA-Seq/
ChIP-Seq analyses of Asxl1 in hematopoietic cells identify a subset of differentially expressed 
genes as direct targets of Asxl1. These findings underscore the importance of Asxl1 in Poly-
comb group function, development, and hematopoiesis.
© 2013 Abdel-Wahab et al.  This article is distributed under the terms of an   
Attribution–Noncommercial–Share  Alike–No  Mirror  Sites  license  for  the  first 
six  months  after  the  publication  date  (see  http://www.rupress.org/terms).  After   
six  months  it  is  available  under  a  Creative  Commons  License  (Attribution– 
Noncommercial–Share  Alike  3.0  Unported  license,  as  described  at  http:// 
creativecommons.org/licenses/by-nc-sa/3.0/).
include somatic mutations in genes with a known 
or putative role in the epigenetic regulation of 
gene expression (Shih et al., 2012). Addition of 
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crossed to germline EIIa-cre mice, IFN-–inducible Mx1-cre, 
and hematopoietic-specific Vav-cre (all as described below). 
Asxl1 protein expression was not detectable in hematopoi-
etic tissue from Vav-cre and Mx1-cre mice (Fig. 2 B), consistent 
with generation of a KO allele.
Germline Asx1 loss results in embryonic lethality  
and craniofacial abnormalities
We characterized the effects of constitutive deletion of Asxl1 
by crossing mice bearing floxed Asxl1 alleles with germline 
EIIa-cre mice. The Asxl1 floxed allele was completely recom-
bined in EIIa-cre Asxl1fl/fl mice (not depicted). We observed 
100% embryonic lethality in mice with germline complete 
deletion of Asxl1 (Asxl1/), whereas mice with heterozy-
gous germline deletion of Asxl1 (Asxl1+/) were born at ex-
pected Mendelian ratios (Fig. 1 C). Asxl1/ mice were no 
longer viable by embryonic day (E) 19.5 and were charac-
terized by microphthalmia/anophthalmia (seen in 12/12 of   
homozygous Asxl1-null embryos examined; Fig. 1, D and E), 
frequent cleft palates (seen in 5/12 of homozygous Asxl1-null 
embryos examined; Fig. 1 E), and multiple skeletal abnormali-
ties (mandibular hypoplasia, loss of hyoid bone formation, and 
posterior homeotic transformations; seen in 4/12 of homozy-
gous Asxl1-null embryos examined; Fig. 1 F). Asxl1+/ were 
viable but exhibited craniofacial dysmorphism in 35% (14/40) 
of adult Asxl1+/ mice examined (Fig. 1 G). Immunopheno-
typic analysis of HSPCs and erythroid precursor cells in fetal 
liver from control, Asxl1+/, and Asxl1/ mice at E14.5 did 
not reveal differences among the genotypes (Fig. 1, H and I).
Hematopoietic-specific deletion of Asxl1 results in MDS
Asxl1 is expressed throughout the adult hematopoietic com-
partment (Fig. 2 A). To elucidate the effects of Asxl1 loss on 
postnatal hematopoiesis, Asxl1fl/fl mice were crossed to Vav-cre 
and IFN-–inducible Mx1-cre transgenic mice for conditional 
deletion of Asxl1 in the hematopoietic compartment (termed 
as Asxl1 KO hereafter). In both cases, Asxl1 protein expression 
was not detectable in hematopoietic tissue (Fig. 2 B). Mice 
with hematopoietic-specific deletion of Asxl1 (Vav-cre Asxl1fl/fl) 
developed progressive BM and splenic hypocellularity relative 
to littermate controls (Cre Asxl1fl/fl) beginning at 6 wk of 
age and likewise evident at 24 wk of age (n = 6–10 mice per 
genotype at each time point examined; Fig. 2 C). Asxl1 KO 
mice, but not littermate controls, developed progressive leu-
kopenia (Fig. 2 D) and anemia (Fig. 2 E) that was most appar-
ent at 6–12 mo of age. Although the hemoglobin (Hb) in 
Asxl1 KO mice was within normal limits (median of 13.4 g/dl, 
range 12.9–14.8 g/dl) in mice <6 mo of age, between 6 and 
12 mo the Hb was a median of 8 g/dl (range 1.94–13.9 g/dl) 
in KO mice relative to a median of 11.4 g/dl in age-matched 
littermate control mice (range 7.17–14.2 g/dl; n = 6–12 mice 
with each genotype at each time point examined; Fig. 2 E). 
Similarly, the WBC count was within normal limits in Asxl1-
null mice at <6 mo of age (median of 7.64 × 109 cells/µl, 
range 4.66–9.6 × 109 cells/µl), the WBC count fell to a me-
dian of 2.51 × 109 cells/µl (range 0.88–5.18 × 109 cells/µl) 
Sex Combs Like 1 (ASXL1) is a Polycomb-associated protein 
that has been shown to be an essential cofactor for the nuclear 
deubiquitinase BAP1 (Dey et al., 2012), as well as a critical 
mediator of the function of the Polycomb repressive complex 2 
(PRC2; Abdel-Wahab et al., 2012). Recurrent somatic loss-
of-function mutations and deletions in ASXL1 are observed 
in MDS, MPN, and AML patients (Gelsi-Boyer et al., 2009). 
ASXL1 mutations are most common in MDS patients (Bejar 
et al., 2011, 2012; Thol et al., 2011; Sanada and Ogawa, 2012), 
including in 15–20% of MDS patients and in 40–60% in pa-
tients with MDS/MPN overlap syndromes (Gelsi-Boyer et al., 
2009; Boultwood et al., 2010; Jankowska et al., 2011). ASXL1 
mutations are associated with adverse overall survival in MDS, 
chronic myelomonocytic leukemia, AML, and MPN (Bejar   
et al., 2011, 2012; Metzeler et al., 2011; Patel et al., 2012; 
Itzykson et al., 2013; Vannucchi et al., 2013), highlighting the 
relevance  of  ASXL1  mutations  to  myeloid  transformation 
and clinical outcome.
More recently, de novo constitutive ASXL1 mutations were 
identified in children with the developmental disorder Bohring-
Opitz syndrome (Hoischen et al., 2011; Magini et al., 2012). 
Although these genetic data strongly implicate ASXL1 muta-
tions in myeloid malignancies and in developmental defects, our 
understanding of the role of Asxl1 in steady-state hematopoiesis, 
hematopoietic stem/progenitor function, and myeloid malig-
nancies has been limited by the lack of a mouse model for con-
ditional and tissue-specific deletion of Asxl1. Fisher et al. (2010a,b) 
investigated the role of Asxl1 in hematopoiesis through the 
creation and analysis of a model of constitutive Asxl1 deletion 
with targeted insertion of a neo cassette into the Asxl1 locus. 
Disruption of Asxl1 expression in this manner resulted in partial 
perinatal lethality. Analysis of the remaining aged (beyond 15 wk 
of age) Asxl1 mutant mice revealed impairment of B and T cell 
lymphopoiesis and myeloid differentiation. However, constitu-
tive Asxl1 loss did not alter long-term reconstitution in com-
petitive repopulation studies using Asxl1-null fetal liver cells 
(Fisher et al., 2010a,b). These results suggested that Asxl1 has an 
important role in normal hematopoiesis; however, the effects of 
somatic loss of Asxl1 in hematopoietic cells were not evaluated. 
Here we investigate the effects of Asxl1 loss in a time- and tissue-
dependent manner through the generation of a mouse model for 
conditional deletion of Asxl1. We also characterized the effect of 
Asxl1 loss on transcriptional output and gene regulation using 
epigenomic and transcriptomic analysis of hematopoietic stem/
progenitor cells (HSPCs) from WT and Asxl1-deficient mice.
RESULTS
Development of a conditional Asxl1 KO allele
To delineate the role of Asxl1 in development and in hema-
topoiesis, we generated a conditional allele targeting Asxl1  
in vivo (Fig. 1, A and B). We used embryonic stem (ES) cell 
targeting to insert two LoxP sites flanking exons 5–10 of Asxl1, 
as well as an Frt-flanked neomycin selection cassette in the up-
stream intron (Fig. 1, A and B). The generated mice (Asxl1fl/fl) 
were initially crossed to a germline Flp-deleter mouse line to 
eliminate  the  neomycin  cassette  and  then  subsequently JEM Vol. 210, No. 12 
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Figure 1.  Generation of a conditional Asxl1 allele and characterization of mice with constitutive Asxl1 loss. (A) Schematic depiction of the 
targeted Asxl1 allele. Exons 5–10 are targeted and flanked by LoxP sites upon Frt-mediated deletion of the Neo cassette. (B) Verification of correct 
homologous recombination of Asxl1-targeted allele using Southern blots on targeted ES cells. (C) Enumeration of offspring derived from mating  
EIIa-cre Asxl1+/ parents. (D and E) Gross pathology (D) and tissue sections (E) of Asxl1/ mice at 14.5 and 18.5 d postcoitus (dpc). (F) Analysis of 
skeletal preparations from germline Asxl1-null mice surviving to E20.5 including hypoplastic mandibles (asterisk), lack of hyoid bone (arrowhead), and 
lower lumbar/sacral posterior homeotic transformations (arrow). (G) Gross phenotype of EIIa-cre Asxl1+/ and littermate control mice on bilateral 
microphthalmia. Bars: (D) 2 mm; (E and F [top]) 1 mm; (F, bottom) 2.5 mm; (G) 0.5 cm. (H) Immunophenotyping of fetal liver at 14.5 dpc on relative 
frequency of LSK cells, MPP cells (LSK, CD48+, CD150 cells), and LT-HSCs (LSK, CD48, CD150+ cells) between mice with germline loss of 0, 1, or 2 
copies of Asxl1. FACS analysis was performed with three to five independent fetal liver samples per genotype. (I) FACS analysis of fetal liver at 14.5 
dpc reveals relative frequency of CD71+ single-positive, CD71/Ter119 double-positive, or Ter119 single-positive cells with constitutive loss of Asxl1. 
Antibody stainings are as indicated, and cells were gated on live cells in the parent gate. Error bars represent ±SD.
in Asxl1 KO mice between the ages of 6 and 12 mo com-
pared with age-matched littermate Asxl1 WT mice (median 
WBC count of 4.51 × 109 cells/µl, range 2.62–13.8 × 109 
cells/µl; Fig. 2 D). The leukopenia was predominantly caused 
by decrements in B220+ mature B cells, CD11b+ Gr1+ neutro-
phils,  and  CD11b+  Gr1  monocytes  as  indicated  by  flow   
cytometric and morphological analysis of peripheral blood 
(Fig. 2, F and G). The age-dependent anemia observed in 2644 Conditional deletion of Asxl1 results in MDS | Abdel-Wahab et al.
Figure 2.  Conditional deletion of Asxl1 results in age-dependent leukopenia and anemia. (A) qRT-PCR showing relative expression level of Asxl1 
in purified progenitor and mature mouse hematopoietic stem and progenitor subsets. (B) Verification of Mx1-cre– and Vav-cre–mediated deletion of 
Asxl1 at the level of protein expression in Western blot of splenocytes. (C) Enumeration of nucleated cells in bilateral femurs and tibiae or whole spleens 
of control (Asxl1fl/fl) and Asxl1 hematopoietic-specific KO mice (Vav-cre Asxl1fl/fl) at 6 as well as 24 wk of age (n = 6–10 mice per genotype at each time 
point examined). (D and E) Enumeration of peripheral WBCs (D) and Hb (E) with postnatal deletion of Asxl1 (performed using Mx1-cre Asxl1fl/fl mice or 
Cre Asxl1fl/fl controls). Counts in aged Asxl1 KO mice are compared with age-matched controls as well as younger KO and control mice (n = 6–12 mice 
per genotype at each time point examined). (F and G) Flow cytometric enumeration of B220+, CD11b+/Gr1+, CD3+, and CD11b+/Gr1 cells in the peripheral 
blood of >6-mo-old Mx1-cre Asxl1fl/fl (KO) and Asxl1fl/fl (C) mice (n = 5 mice per genotype were used for FACS analysis of peripheral blood). The right panel 
reveals peripheral blood FACS analysis. Antibody stainings are as indicated, and cells were gated on live cells in the parent gate. (A and C–F) Error bars 
represent ±SD (A and F); mean ± SEM is shown (C–E); *, P < 0.05; **, P < 0.001 (Mann–Whitney U test).JEM Vol. 210, No. 12 
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myeloid cells (Fig. 3 D), frequent circulating nucleated red 
cells (Fig. 3 D), hypocellular marrow (Fig. 3 B), and dyspla-
sia of erythroid precursors (Fig. 3 C). Previous characteriza-
tion of HSPCs from patients with MDS (Sawada et al., 1993, 
1995) and mouse models of MDS (such as the NUP98-
HOXD13 transgenic mouse model [Choi et al., 2008]) have 
Asxl1 KO mice was accompanied by an increase (median 
1.4- to 2-fold) in CD71+/Ter119 erythroid precursor cells 
in both the BM and spleen, consistent with impaired eryth-
roid differentiation (Fig. 3 A).
Pathological analysis of Asxl1 KO hematopoietic tissues 
at 6 mo of age revealed morphological dysplasia of circulating 
Figure 3.  Deletion of Asxl1 results in 
myeloid and erythroid dysplasia and im-
paired progenitor differentiation consis-
tent with myelodysplasia. (A) Relative 
frequency of CD71+/Ter119 erythroid pre-
cursors in BM and spleen of 6.5-mo-old Mx1-
cre Asxl1fl/fl (KO) and Cre Asxl1fl/fl control 
mice (expressed as percentage of live cells;  
n = 3–5 mice per genotype in each tissue type 
examined by FACS analysis). (B) Histological 
(H&E) analysis of Mx1-cre Asxl1fl/fl and Cre 
Asxl1fl/fl control BM from 6-mo-old littermate 
mice. (C) BM cytospins (Wright-Giemsa) from 
the same mice (arrows indicate erythroid 
precursors with prominent irregular nuclear 
contours). (D) Representative morphology of 
peripheral blood myeloid cells (top) and nucle-
ated RBCs (bottom) in KO mice (Wright-Giemsa 
stain). (E) Number of colonies formed 7 d after 
plating of 1,000 CMP, GMP, or MEP cells into 
methylcellulose from 6-wk-old Vav-cre Asxl1fl/fl 
and littermate control (Cre Asxl11fl/fl control) 
mice. The experiment was performed in bio-
logical duplicate. (F) Photograph of methyl-
cellulose colony plate 7 d after plating of 
MEP cells from 6-wk-old KO and control 
mice. (G) Histological analysis by H&E stain-
ing of liver from 72-wk-old Mx1-cre Asxl1fl/fl 
mice and littermates. (H) Number of colonies 
formed 7 d after plating of 200,000 nucleated 
cells harvested from the liver of 72-wk-old 
Mx1-cre Asxl1fl/fl or littermate control mice in 
methylcellulose containing rmIL-3, rm-SCF, 
rh-IL6, rh-EPO (liver cells from n = 5 mice per 
genotype plated in methylcellulose). (I) Photo-
micrograph of colonies grown from cells 
taken from the liver and plated in methylcel-
lulose is shown on right. Bars: (B) 50 µm;  
(C) 10 µm; (D) 5 µm; (G) 100 µm; (I) 200 µm. 
Error bars represent ±SD; *, P < 0.05 (Mann–
Whitney U test).2646 Conditional deletion of Asxl1 results in MDS | Abdel-Wahab et al.
Figure 4.  Serial noncompetitive transplantation of Asxl1-null cells results in lethal myelodysplastic disorder. (A) Kaplan-Meier survival curve 
of recipient mice transplanted with 70-wk-old Vav-cre Asxl1fl/fl or Cre Asxl1fl/fl littermate control whole BM after secondary and tertiary transplanta-
tion. Also shown is the survival of mice transplanted with purified LSK cells in tertiary transplantation (tertiary transplant of Asxl1fl/fl control LSK cells is 
not shown; no recipient mice from this group died by 40 wk [n = 5]). Cre Asxl1fl/fl littermate controls were similarly transplanted in parallel in each JEM Vol. 210, No. 12 
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dying 24–42 wk after transplant (median of 28 wk). Trans-
plantation of purified lineage Sca-1+ c-KIT+ (LSK) cells 
from the BM of secondary recipients led to a lethal myeloid 
disease in all tertiary transplant recipients with more rapid 
onset (median of 10.3 wk, range 5.1–10.6 wk) than trans-
plantation of unfractionated BM cells from the same sec-
ondary recipients (Fig. 4 A). Disease in transplanted mice was 
characterized by progressive anemia and cachexia (Fig. 4,   
B and C), BM hypocellularity (Fig. 4 D), and an increase in 
the relative frequency of HSPCs in both the BM and the 
spleen (Fig. 4, E and F). This was accompanied by splenomeg-
aly caused by EMH and effacement of splenic architecture 
(Fig. 4, G–I). Anemia in the KO-transplanted recipient mice 
was evident even with gross inspection of bones (Fig. 4 J). As 
in primary Asxl1 KO mice, this anemia occurred despite an 
increase in erythroid precursors in both the BM and spleen 
(Fig. 4, K and L), consistent with a block in erythroid differ-
entiation with Asxl1 loss. This block in erythroid differentiation 
was characterized by a significant increase in CD71/Ter119 
double-positive erythroid precursors in the spleen (Fig. 4 L).
Impaired self-renewal of Asxl1-deficient cells  
is rescued by concomitant Tet2 loss
We next assessed the effects of Asxl1 loss on hematopoietic 
stem cell (HSC) frequency and function. We observed an   
increase in the absolute number of immunophenotypically 
defined HSPCs in Asxl1 KO (Vav-cre Asxl1fl/fl) mice at 6 wk 
of age, including long-term HSCs (LT-HSC; CD150+ CD48 
Lin Sca-1+ c-Kit+; Fig. 5, A and B; quantified as the total 
number of live cells per femur). Although the number of im-
munophenotypic stem/progenitor cells was increased, we ob-
served a decrease in serial plating in vitro in Asxl1 KO cells 
(Fig. 6 A), suggesting a potential defect in self-renewal. To assess 
the effects of Asxl1 deletion in vivo, 500,000 whole BM nu-
cleated cells from 6-wk-old CD45.2 Vav-cre Asxl1fl/fl mice or 
Asxl1fl/fl littermate controls were transplanted in competition 
with an equal number of 6-wk-old CD45.1 competitor BM 
cells into lethally irradiated CD45.1 recipient mice (Fig. 5 C). 
identified an impairment of sorted hematopoietic progeni-
tors to form colonies ex vivo in methylcellulose contain-
ing myeloid and erythroid cytokines. Consistent with these 
prior observations and the impairment in mature myeloid 
and erythroid differentiation seen in Asxl1-deficient mice,   
in vitro analysis of sorted myeloid progenitor (MP) cells from 
6-wk-old Asxl1 KO and control mice revealed a clear decrease 
in colony output of sorted common MPs (CMPs), granulocyte/
macrophage  progenitors  (GMPs),  and  megakaryocyte/ 
erythroid progenitors (MEPs) in KO versus control mice 
(Fig. 3, E and F).
Consistent with the age-dependent development of im-
paired myeloid and erythroid output in Asxl1 KO mice com-
pared with age-matched littermate controls, Asxl1 KO (Mx1-cre 
Asxl1fl/fl) mice were found to have infiltration of liver with he-
matopoietic cells consistent with extramedullary hematopoi-
esis (EMH) with Asxl1 deletion (Fig. 3 G).  To ascertain whether 
this hematopoietic infiltrate represented inflammatory infil-
tration of hematopoietic cells versus EMH, we plated 200,000 
cells harvested from the liver of Asxl1 KO mice and litter-
mate controls in methylcellulose semisolid media containing 
myeloid-erythroid cytokines (rmIL-3, rmSCF, rh-EPO, and 
rh-IL6). Colonies plated with cells derived from Asxl1 KO 
mice alone yielded abundant colonies (Fig. 3, H and I), dem-
onstrating EMH.
Cell-autonomous effects of Asxl1 loss
Transplantation of whole BM from Asxl1 KO (Vav-cre Asxl1fl/fl) 
mice into lethally irradiated recipients resulted in a penetrant, 
lethal hematopoietic disorder (Fig. 4 A), indicating that the 
phenotype induced by Asxl1 loss was cell autonomous. For 
example, transplantation of whole BM from 70-wk-old pri-
mary Asxl1 KO mice into lethally irradiated recipients re-
sulted in the death of recipient mice at a median of 50 wk 
after transplant (range 41–74 wk), whereas no mice trans-
planted with Asxl1 WT BM died during this period of ob-
servation. Furthermore, serial transplantation into tertiary 
recipients resulted in shorter latency of disease, with mice 
experiment. Four to six recipient mice were transplanted in each experiment. (B) Hematocrit over time of secondary recipient mice transplanted with 
Asxl1-null or littermate control whole BM in a noncompetitive manner. The dashed line represents the lower limit of normal hematocrit for C57BL/6 
mice (n = 4–6 mice per genotype at each time point). (C) Body weight of secondarily transplanted mice at 50 wk after transplantation (n = 4 mice per 
genotype). (D) BM histopathology of secondary recipient mice transplanted with Asxl1-null or littermate control whole BM at 50 wk. (E) Relative fre-
quency of LSK cells, MPP cells (LSK+, CD150, CD48+), and LT-HSCs (LSK+ CD150+ CD48) in BM and spleen at 50 wk after noncompetitive secondary 
transplantation. Frequencies are expressed as frequency of live cells (n = 4 mice per genotype examined for FACS experiments). (F) Relative frequency of 
MP (lineage c-Kit+ Sca-1), CMP (lineage, c-Kit+, Sca-1, FcR, CD34+), GMP (lineage c-Kit+ Sca-1, FcR+ CD34+), and MEP (lineage c-Kit+ Sca-1 
FcR CD34) cells at 50 wk after noncompetitive secondary transplantation. Frequencies are expressed as a frequency of live cells. (G) Photographs  
of spleens from secondary recipient mice transplanted with Vav-cre Asxl1fl/fl or Cre Asxl1fl/fl littermate control whole BM 50 wk after lethal irradiation. 
(H) Weight of the same spleens as shown in G (n = 4 mice per genotype). (I) Histopathology of spleens from secondary recipient mice transplanted with 
Asxl1-null or WT littermate control whole BM 50 wk after noncompetitive secondary transplantation revealing loss of normal splenic architecture. 
(J) Photographs of representative femur (top) and tibia (bottom) from secondary recipient mice transplanted with Vav-cre Asxl1fl/fl or Cre Asxl1fl/fl  
littermate control whole BM 50 wk after noncompetitive secondary transplantation. Bars: (D and I) 50 µm; (J) 2 mm. (K) Relative quantification of 
CD71+/Ter119 and CD71/Ter119 double-positive cells from BM and spleen of secondary recipient mice transplanted with Vav-cre Asxl1fl/fl or Cre  
Asxl1fl/fl littermate control whole BM 50 wk after noncompetitive secondary transplantation. Frequencies are expressed as a percentage of live cells  
(n = 4 mice per genotype examined by FACS analysis). (L) Representative FACS plots of data shown in K from splenocytes. Staining is as shown, and live 
cells were gated in parent gate. Error bars represent ±SD; *, P < 0.05 (Mann–Whitney U test).
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CD45.1 secondary recipient mice (Fig. 5 D). Serial competi-
tive transplantation revealed an even further competitive dis-
advantage in Asxl1-deficient HSPCs (Fig. 5 D).
Given that MDS is characterized by impaired myeloid 
differentiation, multilineage cytopenias, and clonal dominance 
over time, we hypothesized that mutations that occur in con-
cert with ASXL1 deletion/mutation in MDS might com-
pensate for the impaired self-renewal observed with Asxl1 
loss. Previous studies have shown that mutations in TET2 are 
most commonly observed with mutations in ASXL1 in MDS 
(Bejar et al., 2011, 2012). We and others previously demon-
strated increased hematopoietic self-renewal in Tet2-deficient 
mice (Ko et al., 2011; Li et al., 2011; Moran-Crusio et al., 
Chimerism was assessed based on evaluation of the ratio of 
CD45.1 to CD45.2 peripheral blood mononuclear cells be-
ginning 2 wk after transplantation and then monitored on   
a monthly basis until 16 wk thereafter. Consistent with the   
in vitro data, we observed a clear reduction in self-renewal   
in vivo. Asxl1 KO HSPCs had a significant disadvantage in 
competitive transplantation that was further accentuated with 
serial transplantation (Fig. 5, C and D).
After the final assessment of chimerism in the primary 
competitive transplantation experiments, primary recipient 
mice were sacrificed and a serial competitive transplantation 
experiment was performed by transplanting 1 million whole 
BM cells from primary recipient mice into lethally irradiated 
Figure 5.  Asxl1/ mice have increased 
stem/progenitor cells but impaired self-
renewal. (A) Flow cytometric enumeration of 
BM LSK cells, LT-HSCs (LSK CD150+ CD48), 
and MPP cells (LSK CD150 CD48+) in WT 
(Asxl1fl/fl) and KO (Vav-cre Asxl1fl/fl) mice at  
6 wk of age (n = 4–6 mice per genotype as 
indicated). Data are expressed as total num-
ber of live cells per femur. (B) Representative 
FACS analysis of BM stem cell populations of 
Asxl1/ (Vav-cre Asxl1fl/fl) and WT (Asxl1fl/fl) 
at 6 wk. Antibody stains are as indicated and 
parent gate is live, lineage cells. (C) Sche-
matic depiction of the competitive transplan-
tation assay. Asxl1fl/fl and Vav-cre Asxl1fl/fl are 
positive for CD45.2, whereas WT competitor 
cells are positive for CD45.1. Recipient mice 
are also CD45.1. Representative FACS plots 
of the percentage of CD45.1 versus CD45.2 
total chimerism in the peripheral blood of 
recipient animals at 16 wk after competitive 
transplantation is shown. (D) Percentage of 
CD45.1 versus CD45.2 total chimerism in the 
peripheral blood of recipient animals at 4 and 
16 wk in primary competitive transplant and 
serial secondary competitive transplants are 
shown (n = 5 recipient mice for each geno-
type; C, control; KO, Asxl1 KO). The experi-
ment was performed in biological duplicate. 
Error bars represent ±SD; *, P < 0.05 (Mann–
Whitney U test).JEM Vol. 210, No. 12 
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compound Asxl1/Tet2 loss (Fig. 6 A). More importantly, 
competitive transplantation experiments revealed a competi-
tive advantage for Vav-cre Asxl1fl/fl Tet2fl/fl whole BM com-
pared with matched CD45.1 competitor BM (Figs. 6, B–D). 
These data demonstrate that concurrent Tet2 loss restores the 
self-renewal defect induced by Asxl1 loss.
2011; Quivoron et al., 2011). We analyzed the in vitro and   
in vivo phenotype of Vav-cre Asxl1fl/fl Tet2fl/fl hematopoietic 
cells compared with control, Vav-cre Asxl1fl/fl, and Vav-cre Tet2fl/fl 
mice (Fig. 6 A). Colony assays of whole BM cells from the 
same mice revealed reduced serial replating activity of Asxl1 
KO cells but restored serial-replating capacity of cells with 
Figure 6.  Combined loss of Asxl1 and 
Tet2 rescues the impaired self-renewal 
of Asxl1-deficient HSCs. (A) Enumeration 
of colonies and serial replating capacity of 
20,000 whole BM cells from 6-wk-old lit-
termate mice with hematopoietic-specific 
deletion of Asxl1 (Vav-cre Asxl1fl/fl), Tet2 
(Vav-cre Tet2fl/fl), or both (Vav-cre Asxl1fl/fl 
Tet2fl/fl). (B) Schematic depiction of the 
competitive transplantation experiment. 
Control, Vav-cre Asxl1fl/fl, Vav-cre Tet2fl/fl, 
and Vav-cre Asxl1fl/flTet2fl/fl cells are positive 
for CD45.2, whereas WT competitor cells are 
positive for CD45.1. On the right, monthly 
assessment of donor chimerism in the pe-
ripheral blood of recipient animals is shown 
up to 16 wk after transplant (n = 5 recipi-
ent mice were used for each genotype and 
experiment was performed in biological 
duplicate). 16-wk chimerism was signifi-
cantly higher in Tet2/ transplanted mice 
compared with all other genotypes. (C) Rep-
resentative FACS analysis of peripheral blood 
of mice transplanted with each genotype at 
16 wk. Staining schemes are as indicated and 
parental gate was live cells. (D) Proportion of 
CD45.2+ peripheral blood cells of each lin-
eage at 16 wk in mice transplanted with each 
genotype (n = 5 mice analyzed for each 
genotype) as determined by FACS analysis. 
Each competitive transplantation experi-
ment was performed in biological duplicate 
with five recipient mice per genotype in 
each experiment. Error bars represent ±SD;  
*, P < 0.05 (Mann–Whitney U test).2650 Conditional deletion of Asxl1 results in MDS | Abdel-Wahab et al.
Figure 7.  Concomitant deletion of Asxl1 and Tet2 results in myelodysplasia in mice. (A) Kaplan-Meier survival curve of primary Cre Asxl1fl/fl (n = 5), 
Mx1-cre Asxl1fl/fl (n = 12), Mx1-cre Tet2fl/fl (n = 6), Mx1-cre Asxl1fl/fl Tet2fl/fl (n = 10 mice per genotype). Mice were treated with polyI:polyC at 4 wk after 
birth and then followed for 50 wk. (B) Peripheral WBC count and differential of recipient mice transplanted with BM from 6-wk-old Mx1-cre Asxl1 WT 
Tet2 WT (control; C), Mx1-cre Asxl1fl/fl (Asxl1 KO), Mx1-cre Tet2fl/fl (Tet2 KO), and Mx1-cre Asxl1fl/fl Tet2fl/fl (Asxl1/Tet2 DKO) mice 66 wk after transplantation JEM Vol. 210, No. 12 
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of morphological dysplasia in precursor cells, decrease in pe-
ripheral circulating mature cells, and concurrent increased total 
BM cells and HSPCs were suggestive of the presence of MDS 
in the Asxl1/Tet2 compound–deficient mice.
Transcriptional effects of Asxl1 loss
To understand the basis for the impaired myeloid differentia-
tion and self-renewal observed with Asxl1 loss, we performed 
expression analysis of sorted LSK and MP cells from cyto-
penic 1-yr-old Asxl1 KO mice and age-matched littermate 
controls (Fig. 8, A and B; and Tables S1 and S2). Analysis   
of RNA-Seq data identified a set of differentially expressed 
genes in Asxl1 KO LSK cells (797 genes) and MP cells (1,095 
genes). Integrative analysis identified a set of 75 genes that 
were differentially expressed in Asxl1 KO LSK and MP cells, 
including 41 up-regulated and 34 down-regulated genes in 
Asxl1 KO mice relative to controls (Fig. 8 B).
Consistent with previous in vitro data (Abdel-Wahab   
et al., 2012), we observed increased expression of posterior 
HoxA genes in Asxl1 KO LSK cells, including HoxA7 and 
HoxA9  as  well  as  the  Hox-associated  transcription  factors 
Hes5 and Gdf11 (Fig. 8 C). Meis1 was not up-regulated, with 
Asxl1 loss consistent with a previous study in in vitro systems 
(Fig. 8 C; Abdel-Wahab et al., 2012). We also noted a progres-
sive, age-dependent increase p16INK4a expression in LT-HSCs 
and multipotent progenitor (MPP) cells (LSK CD48+ CD150) 
of Asxl1 KO mice compared with age-matched controls   
(Fig. 8 D). The p16INK4a locus is a known PRC2 target (Jacobs 
et al., 1999; Bracken et al., 2007; Hidalgo et al., 2012; Tanaka 
et al., 2012), and in vitro loss of Asxl1 has been linked to de-
fective Polycomb repression and reduced H3K27 methylation 
(Abdel-Wahab et al., 2012). Given the increase in p16INK4a 
expression in KO MPP cells from Asxl1 KO mice, we exam-
ined the in vivo cell proliferation of MPP cells from 72-wk-old 
Asxl1 KO (Vav-cre Asxl1fl/fl) versus control mice (Cre Asxl1fl/fl) 
via an in vivo BrdU incorporation assay. The MPP cells of 
Asxl1  KO  mice  showed  a  significant  decrease  in  S-phase 
compared with littermate control cells (Fig. 8 E). Flow cyto-
metric quantitative assessment of apoptosis in LSK cells of the 
same mice revealed a significant increase in Annexin-V+/DAPI 
and Annexin-V+/DAPI+ LSK cells (Fig. 8 F; n = 5 mice per 
group) consistent with cell cycle exit and an increase in apop-
tosis in vivo.
To understand what transcriptional differences might exist 
between mice with compound deletion of Asxl1 and Tet2 
Concomitant deletion of Asxl1 and Tet2 in vivo results in MDS
Given the restoration of self-renewal noted in mice with   
concomitant deletion of Tet2 and Asxl1 in the context of a 
competitive transplantation experiment, we investigated the 
phenotype of mice with compound deletion of Tet2 and Asxl1  
compared with mice with deletion of each gene alone. A co-
hort of primary Cre Asxl1  WT Tet2  WT, Mx1-cre Asxl1fl/fl (Asxl1 
KO), Mx1-cre Tet2fl/fl (Tet2 KO), and Mx1-cre Asxl1fl/fl Tet2fl/fl 
(double KO [DKO]) mice were treated with polyinosinic-
polycytidylic acid (polyI:polyC) at 4 wk of life and followed 
up to 50 wk after birth (46 wk after polyI:polyC adminis-
tration). At the end of this observation period, 40% of DKO 
mice (4/10) and 17.7% of Tet2 KO died (1/6), whereas no 
Asxl1 KO (0/12) or control mice (0/5) died (Fig. 7 A).
For further analyses, to obtain a sufficiently large number 
of mice for each genotype, BM from 6-wk-old CD45.2 Mx1-cre 
Asxl1 WT Tet2 WT, Mx1-cre Asxl1fl/fl (Asxl1 KO), Mx1-cre 
Tet2fl/fl (Tet2 KO), and Mx1-cre Asxl1fl/fl Tet2fl/fl (DKO) mice 
were transplanted into lethally irradiated CD45.1 recipient 
mice (10 recipient mice per genotype). All recipient mice   
(including those transplanted with Mx1-cre Asxl1 WT Tet2 
WT BM) were then treated with polyI:polyC 2 wk after 
transplantation to delete Tet2 and/or Asxl1. At 72 wk after 
transplant, Asxl1-null and/or Asxl1/Tet2 compound–null 
mice had significantly lower WBC counts and hematocrit 
compared with WT or Tet2 single KO control mice (Fig. 7,   
B and C). As seen in mice with primary deletion of Asxl1, 
Asxl1 KO mice here had reduced BM cellularity compared 
with control or Tet2 KO mice (Fig. 7 D). However, despite 
the similar blood counts between Asxl1 KO and DKO mice, 
the DKO had greater BM cellularity than mice with deletion 
of just Asxl1 or even Tet2 (Fig. 7 D). Examination of the 
HSPC compartment across mice with the four genotypes   
at 72 wk indicated a greater total number as well as relative 
frequency of LSK and MP cells in the BM of DKO mice 
compared with other groups (Fig. 7, E and F). Morphologi-
cally, BM of Asxl1 KO mice was characterized by the pres-
ence of dysplastic erythroid precursor cells as seen in primary 
Asxl1 KO mice earlier (Fig. 7 G). The BM of DKO mice like-
wise was characterized by a similar presence of dysplastic eryth-
roid precursors as well as dysplastic myeloid cells (Fig. 7 G) 
but lacked the hypocellularity seen in the BM of mice with 
Asxl1 deletion alone (Fig. 7 D). Histological analysis of liver tis-
sue revealed increased hematopoietic cell infiltration in DKO 
mice compared with the other groups (Fig. 7 H). The presence 
(68 wk after polyI:polyC administration to recipient mice; n = 10 mice per genotype). Differential was determined by flow cytometric analysis of periph-
eral blood. (C and D) Hematocrit (C) and total number (D) of nucleated BM cells of same mice as shown in B. Horizontal lines indicate the mean. (E) Rep-
resentative flow cytometric assessment of relative frequencies of MP and LSK cells in 72-wk-old mice. Parent population was live, lineage cells. (F) Total 
numbers of LSK and MP cells (lineage Sca-1 c-Kit+) in mice from each genotype at 72 wk of age. This was determined by flow cytometric quantification 
of living LSK and MP cells from c-KIT–enriched BM cells harvested from spine plus bilateral femurs, tibiae, and humeri of each mouse from each genotype 
at 72 wk of age (n = 3 mice per group). (G) Wright-Giemsa stain of BM representative erythroid precursor from cytospins of 72-wk-old control, Asxl1 KO, 
Tet2 KO, or Asx1/Tet2 DKO mice. Arrows indicate multinuclearity and nuclear fragmentation in erythroid precursors. (H) Representation histological sec-
tions of liver from 72-wk-old control, Asxl1 KO, Tet2 KO, or Asx1/Tet2 DKO mice Bars: (G) 5 µm; (H) 50 µm. For A and B, n = 10 mice per group; for C–H,  
n = 3 mice per group. Error bars represent ±SD; *, P < 0.05 (Mann–Whitney U test).
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Figure 8.  Identification of genes significantly dysregulated with deletion of Asxl1 alone and in concert with deletion of Tet2 and their 
functional impact. (A) Volcano plot of differentially expressed transcripts from RNA-Seq data of 1-yr-old control versus littermate Asxl1 KO (Mx1-cre 
Asxl1fl/fl) LSK and MP (lineage Sca-1 c-Kit+) cells (experiment included cells from two individual mice per genotype). (B) Venn diagrams of genes  
significantly up- and down-regulated with Asxl1 loss in LSK and MP (lineage, Sca-1, cKit+) cells from 1-yr-old Mx1-cre Asxl1fl/fl mice and littermate JEM Vol. 210, No. 12 
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H3K27 trimethyl (H3K27me3) levels were significantly re-
duced after Asxl1 deletion (Fig. 9 A) despite sustained expres-
sion of the core PRC2 components (Fig. 9 B).
Although the effects of Asxl1 loss on transcription caused 
by alterations in histone posttranslational modifications have 
previously been described (Abdel-Wahab et al., 2012), direct 
transcriptional  targets  of  Asxl1  through  characterization  of 
Asxl1 binding throughout the genome have never previously 
been assessed. We therefore performed chromatin immuno-
precipitation (ChIP) for Asxl1 followed by DNA sequencing 
(ChIP-Seq) in purified mouse myeloid hematopoietic cells. 
Asxl1 was found to bind to many sites throughout the genome 
with the majority of significantly enriched Asxl1 peaks (78%) 
located at CpG-rich transcription start sites (TSSs; Fig. 9, C–E; 
and Tables S4 and S5). Motif enrichment analysis of the Asxl1-
binding sites revealed that the top occurring motifs are most 
similar to known binding sites of the Ets family of transcription 
factors (Fig. 9 F; P = 1 × 1059, percent target = 40.1%, and 
percent background = 21.4%). A significant subset of genes 
with dysregulated expression in Asxl1 KO LSK/MP cells were 
confirmed as direct targets of Asxl1 in our ChIP-Seq analysis 
(14 up-regulated and 9 down-regulated genes; Table 1).
DISCUSSION
Here we show that conditional deletion of Asxl1, a gene 
commonly mutated in human MDS, in hematopoietic cells 
resulted in the development of progressive anemia and leuko-
penia with concomitant multilineage myeloid dysplasia in 
vivo. Asxl1 deletion was associated with an increase in the 
frequency and total number of HSPCs, increased apoptosis, 
and altered cell cycle distribution of HSPCs in vivo. Asxl1   
loss also led to a reduction in myeloid colony output. MDS   
is characterized by variable cytopenias caused by ineffective 
production of mature granulocyte, erythroid, and/or mega-
karyocyte populations and a risk of transformation to AML. 
Functional characterization of primary samples from patients 
with MDS has identified an expansion of the primitive HSC 
compartment (comprised of long-term and short-term HSCs; 
Will et al., 2012; Pang et al., 2013), the presence of specific ge-
netic alterations throughout the diseased clone originating in 
the most immature HSCs (Nilsson et al., 2000, 2007; Tehranchi 
relative to mice with deletion of Asxl1, Tet2, or neither gene, 
we performed RNA-Seq on LSK cells sorted from the BM of 
6-wk-old Mx1-cre Asxl1 WT Tet2 WT, Mx1-cre Asxl1fl/fl, Mx1-cre 
Tet2fl/fl, and Mx1-cre Asxl1fl/fl Tet2fl/fl mice (Fig. 8 G and Table S3). 
Of the 1,744 genes significantly up-regulated in any KO mice 
relative to controls, the majority of these genes were shared 
between Asxl1 KO and Tet2 KO LSKs but not DKO LSKs 
(32.6% of up-regulated genes [569/1,744 genes]), followed 
by genes shared between Asxl1 KO, Tet2 KO, and DKO mice 
(29.2% of up-regulated genes [510/1,744 genes]). Likewise, 
for the 1,363 significantly down-regulated genes, the major-
ity of these were shared between Asxl1 KO and Tet2 KO 
LSKs  but  not  DKO  LSKs  (37.6%  of  up-regulated  genes 
[513/1,363 genes]), followed by genes shared between Asxl1 
KO, Tet2 KO, and DKO mice (28.0% of up-regulated genes 
[382/1,363 genes]).
We next performed gene set enrichment analysis (GSEA) 
to identify gene sets enriched in HSPCs from Asxl1 KO 
mice or Asxl1/Tet2 DKO mice compared with other groups   
(Subramanian et al., 2005). We identified gene sets enriched 
in HSCs (Ramalho-Santos et al., 2002) and apoptosis (http://
www.genome.jp/kegg/pathway/hsa/hsa04210.html) in mice 
with Asxl1 deletion and with concomitant Asxl1/Tet2 dele-
tion (Fig. 8 H). We also identified gene sets that were uniquely 
enriched in Tet2/Asxl1 DKO mice and not seen in the other 
groups. This prominently included gene sets characteristic 
of apoptosis signatures, purified HSPCs (Ivanova et al., 2002), 
cell cycle regulators (http://www.genome.jp/kegg/pathway/
hsa/hsa04110.html), and signatures from MLL-rearranged 
primary leukemias (Fig. 8 I; Ross et al., 2003; Mullighan   
et al., 2007).
Genome-wide binding of Asxl1 and global effects  
of Asxl1 loss on the epigenome
Asxl1 has been shown to interact with epigenetic modifiers 
known to impact transcription (Abdel-Wahab et al., 2012; Dey 
et al., 2012). This includes binding to the core members of the 
PRC2, where loss of ASXL1 has previously been found to re-
sult in global down-regulation of histone H3 lysine 27 (H3K27) 
methylation (Abdel-Wahab et al., 2012) in vitro and in ex vivo 
ASXL1 mutant primary patient samples. Consistent with this, 
Cre controls as identified in A. (C) qRT-PCR analysis of HoxA and Hox-associated transcription factor genes in LSK cells of 1-yr-old Cre Asxl1fl/fl con-
trol versus littermate Vav-cre Asxl1fl/fl. (D) qRT-PCR analysis of p16INK4a in LT-HSCs (lineage, Sca-1+, c-Kit+, CD150+, CD48) and MPP cells (lineage, 
Sca-1+, c-Kit+, CD150, CD48+) from 6-wk- and 6-mo-old control (C) versus littermate Vav-cre Asxl1fl/fl (KO) mice. (E) Cell cycle analysis of MPPs from 
72-wk-old Vav-cre Asxl1fl/fl or littermate Cre Asxl1fl/fl control mice with in vivo BrdU administration. Representative FACS plot analysis showing gating 
on MPP cells followed by BrdU versus DAPI stain is shown on the left (parent gate is LSK cells). Relative quantification of the percentage of MPP cells in S, 
G2/M, and G0/1 phase is shown on the right (n = 5 mice per group). (F) Assessment of the proportion of HSPCs undergoing apoptosis was performed by 
Annexin V/DAPI stain of LSK cells from 72-wk-old Vav-cre Asxl1fl/fl mice or Cre Asxl1fl/fl littermate controls. Representative FACS plot analysis showing 
gating on LSK cells followed by Annexin V versus DAPI stain is shown on the left (parent gate is lineage cells). Relative quantification of the percent-
age of Annexin V+/DAPI and Annexin V+/DAPI+ LSK cells is shown on the right (n = 5 mice per group). (G) Comparison of significant differentially ex-
pressed genes in LSK cells from 6-wk-old Mx1-cre Asxl1fl/fl, Mx1-cre Tet2fl/fl, or Mx1-cre Asxl1fl/fl Tet2fl/fl relative to controls (or Mx1-cre Asxl1 WT Tet2 WT).  
99 genes are uniquely down-regulated in Asxl1/Tet2 DKO mice relative to all other genotypes (left), whereas 49 genes are significantly up-regulated (right). 
(H) GSEA of overlapping and statistically significant gene sets enriched in the LSK cells of mice with deletion of Asxl1 alone or with combined Asxl1 and 
Tet2 deletion. (I) Gene sets uniquely enriched in mice with concomitant deletion of Asxl1 and Tet2 relative to all other genotypes as determined by 
GSEA. Error bars represent ±SD; *, P < 0.05 (Mann–Whitney U test).
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Prior studies of the effects of Asxl1 loss on development and 
hematopoiesis were performed using a constitutive Asxl1 KO 
mouse model (Fisher et al., 2010a,b). Our conditional model al-
lows for evaluation of the effects of postnatal deletion of Asxl1 
and obviates the problems associated with a high frequency of 
perinatal lethality in mice with constitutive Asxl1 deletion. No-
tably, Fisher et al. (2010a,b) identified a 72% reduction in the   
expected number of Asxl1 homozygous KO mice by postnatal 
day 21; when mice were backcrossed more than eight genera-
tions to a consistent genetic background, KO mice were 100% 
embryonic lethal, preventing analysis of adult constitutive Asxl1  
KO mice. Similar to the germline model, we observed an age- 
dependent decrease in mature B lymphocytes, splenomegaly 
caused by EMH, and decreased formation of myeloid and eryth-
roid colonies from Asxl1 KO cells (Fisher et al., 2010a,b). In 
addition, Fisher et al. (2010a,b) observed dysregulated expression 
of HoxA genes and homeotic transformation of homozygous 
Asxl1 mutant embryos, consistent with the current Asxl1 germ-
line and conditional KO models described in this study.
Despite these similarities, several differences exist between 
the two models. First, no reproducible differences in periph-
eral blood counts, BM cellularity, or BM cell morphology were 
seen in Asxl1 constitutive KO mice. In contrast, mice with con-
ditional, homozygous, postnatal deletion of Asxl1 developed 
leukopenia, anemia, myeloerythroid dysplasia, and BM hypo-
cellularity starting at 6 mo of life. This could be caused by dif-
ferences in the strain of the mice analyzed, the timing of Asxl1 
loss, or cell-nonautonomous effects observed in the constitu-
tive KO model.
Of note, the more profound hematologic abnormalities 
seen with serial competitive and noncompetitive transplantation 
et al., 2010; Will et al., 2012; Pang et al., 2013), dysplastic clo-
nogenic activity of HSCs with reduced in vitro colony for-
mation from MDS-derived HSCs (Sawada et al., 1993, 1995; 
Will et al., 2012), and an increase in the frequency and abso-
lute number of HSPCs in the setting of decreased mature   
circulating cells with a concomitant increase in apoptosis of 
HSPCs in MDS patients (Sawada et al., 1993, 1995; Pang   
et al., 2013). Collectively, the phenotype of Asxl1 loss recapit-
ulates these central features of human MDS.
One aspect of the Asxl1 conditional KO mouse model 
that differs from human MDS is the BM hypocellularity ob-
served in Asxl1 KO mice, in contrast to the increased BM 
cellularity in most MDS patients. Nevertheless, the impaired 
production of mature myeloid and erythroid cells in the con-
text of an increased relative and total numbers of HSPCs in 
Asxl1 conditional KO mice does recapitulate key features of 
human MDS. Moreover, concomitant loss of Asxl1 and Tet2, 
which are commonly mutated in concert in human MDS,   
resulted in increased BM cellularity and disease severity with 
pathological evidence of multilineage dysplasia.
In contrast to MPN and AML, there are few previously 
described models of MDS, and to date no models of MDS 
based on mutations in recurrently mutated MDS disease al-
leles. The most widely used model of MDS is based on trans-
genic expression of a NUP98-HOXD13 fusion allele (Lin   
et al., 2005). Although this model has many of the character-
istic features of human MDS, the NUP98-HOXD13 fusion 
was identified in a young patient with therapy-related AML 
(Raza-Egilmez et al., 1998) and has not been identified in 
MDS patients to date. In contrast, ASXL1 mutations occur in 
15–20% of patients with MDS.
Figure 9.  Effect of Asxl1 loss in vivo on 
H3K27me3 and identification of Asxl1-
regulated genes ChIP-Seq. (A) Western blot 
analysis of H3K27me3 and total histone H3 in 
splenocytes of 6-wk-old Vav-cre Asxl1fl/fl mice 
relative to littermate control. (B) Levels of core 
PRC2 members Ezh2, Suz12, and Eed in sple-
nocytes of same mice as shown in A. (C) Char-
acterization of Asxl1-binding sites identified 
by anti-Asxl1 ChIP-Seq analysis in mouse WT 
BMDMs. (D) Heat map representation of Asxl1 
ChIP-Seq signal centered around TSSs (±2 kb) 
of CpG (left) and non-CpG (right) promoters. 
(E) Mean Asxl1 ChIP-Seq signal density of CpG 
and non-CpG promoters centered around the 
TSS ± 10 kb. (F) Motif enrichment analysis of 
Asxl1-binding sites identified significant en-
richment of Ets transcription factor binding 
sites (P = 1 ×1059, percent target = 40.1%, 
and percent background = 21.4%).JEM Vol. 210, No. 12 
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increased BM cellularity, and decreased numbers of circulat-
ing mature cells compared with single-gene KO mice. This 
phenotype is consistent with more severe MDS and suggests 
a functional interdependency between these two disease al-
leles in MDS. Subsequent studies may identify additional dis-
ease alleles that can rescue the self-renewal defect seen in 
ASXL1-deficient stem cells and may lead to the identifica-
tion of additional mutational interdependencies in MDS and 
in other malignant contexts.
We previously demonstrated that loss of ASXL1 in vitro 
results in global down-regulation in H3K27me3 (Abdel-Wahab 
et al., 2012), the repressive histone modification placed by   
the PRC2. Here we demonstrate that Asxl1 deletion in the 
hematopoietic compartment results in reduced H3K27me3 
in vivo. We used ChIP-Seq for Asxl1 itself to show that Asxl1 
is enriched at gene promoter regions throughout the genome, 
suggesting a potential role for Asxl1 in direct regulation of 
gene transcription. In addition, motif enrichment analysis of 
of Asxl1 conditional KO hematopoietic cells here have no 
counterpart in the study of the prior constitutive KO model 
as  serial  transplantation  was  not  performed  in  the  prior 
study (Fisher et al., 2010b). The marked impairment in serial 
transplantability observed with Asxl1 loss is consistent with the 
progressive defects in HSC function observed in mice with 
other alterations in other Polycomb group functions (Ohta   
et al., 2002).
Although  noncompetitive  transplantation  experiments 
demonstrated that the MDS phenotype was cell autonomous, 
Asxl1 deficiency was associated with a defect in HSC self- 
renewal in competitive transplantation assays and in in vitro 
colony formation. These data suggested that concurrent ge-
netic or epigenetic alterations in ASXL1 mutant MDS cells 
must promote self-renewal to allow for clonal dominance of 
MDS cells. Indeed, concurrent Tet2 loss restored the self-renewal 
defect induced by Asxl1 loss. Moreover, mice with concomitant 
loss of Asxl1 and Tet2 developed a larger increase in HSPCs, 
Table 1.  Genes directly regulated by Asxl1 as determined by differential expression in HSPCs with Asxl1 deletion and directly 
bound by Asxl1
Gene MPs LSK cells Anti-Asxl1 ChIP-Seq
log2 (fold change) P-value log2 (fold change) P-value Peak p-value Fold enrichment Peak FDR
Tmem87a 3.91 9.60 × 106 3.11 3.68 × 106 2.78 × 107 4.21 0.29
Pusl1 1.54 2.21 × 107 1.30 1.29 × 103 3.04 × 108 5.24 0.15
Ddx23 1.45 1.15 × 1010 1.09 1.79 × 103 7.45 × 1015 6.93 0.09
Pan3 1.01 1.36 × 105 0.79 8.21 × 104 4.49 × 1029 9.3 0
Srrm2 0.86 6.02 × 108 0.98 1.61 × 106 1.85 × 1012 4.49 0.06
Dusp6 0.80 4.11 × 104 0.63 2.45 × 103 4.48 × 1030 8.43 0
Cdca2 0.77 6.77 × 108 0.62 3.84 × 104 3.78 × 108 3.6 0.16
Apobec3 0.54 2.25 × 1010 0.36 8.29 × 104 4.48 × 1010 6.18 0.09
Cdc40 0.41 1.68 × 104 0.59 1.93 × 105 4.79 × 1010 5.91 0.09
Rpl30 0.39 1.73 × 1010 0.31 5.74 × 105 1.57 × 1022 6.99 0
Rad51 0.39 3.17 × 103 0.51 3.48 × 103 2.28 × 1010 7.16 0.1
Nbr1 0.34 4.65 × 108 0.43 0.00 4.04 × 1019 5.69 0
Slc24a6 0.30 4.66 × 104 0.82 3.24 × 1010 7.52 × 1011 8.09 0.1
Dhrs3 0.28 4.27 × 103 0.37 2.16 × 104 4.33 × 1049 5.15 0
Cdk2 0.23 1.51 × 104 0.21 3.94 × 104 1.06 × 1016 7.89 0.11
Ifngr1 0.18 4.59 × 103 0.38 1.99 × 104 3.02 × 1020 11.89 0
Hsp90ab1 0.16 1.08 × 103 0.24 9.11 × 105 1.41 × 1045 12.71 0
Mtmr9 0.44 4.53 × 104 0.47 3.62 × 104 4.07 × 1011 7.19 0.11
Ppp1cb 0.48 1.35 × 108 0.64 2.14 × 107 5.79 × 1012 4.77 0.09
Mthfr 0.51 1.65 × 103 0.47 1.21 × 103 2.47 × 109 4.82 0.11
Ncf4 0.52 7.21 × 109 0.66 4.38 × 105 2.16 × 1018 7.53 0.07
Slc25a19 0.96 7.68 × 1011 0.75 3.50 × 106 2.24 × 107 6.64 0.28
Rpl29 1.18 0.00 0.76 0.00 2.47 × 109 5.96 0.11
Mettl23 1.33 8.43 × 1010 1.10 1.21 × 105 1.10 × 107 3.68 0.2
Caskin2 1.54 3.42 × 105 2.45 1.53 × 104 4.97 × 1013 5.6 0.07
Thbs1 1.75 4.71 × 107 1.84 1.63 × 106 9.53 × 108 5.06 0.19
FDR, false discovery rate. Differentially expressed genes in RNA sequencing of MPs (lineage Sca-1 c-KIT+ cells) from 1-yr-old Mx1-cre Asxl1fl/fl mice relative to Cre Asxl1fl/fl 
littermate controls. Differentially expressed genes in RNA sequencing of LSK cells (lineage Sca-1+ c-KIT+ cells) from 1-yr-old Mx1-cre Asxl1fl/fl mice relative to Cre Asxl1fl/fl 
littermate controls. Data derived from anti-Asxl1 ChIP-Seq in WT C57BL/6H BMDMs.2656 Conditional deletion of Asxl1 results in MDS | Abdel-Wahab et al.
Hybrid) mouse strains was used as WT controls. Positive ES clones were ex-
panded and injected into blastocysts.
The generated mice (Asxl1fl/fl) were initially crossed to a germline Flp-
deleter (The Jackson Laboratory), to eliminate the neomycin cassette, and 
subsequently to the IFN-–inducible Mx1-cre (The Jackson Laboratory), the 
hematopoietic-specific Vav-cre, and the germline EIIa-cre (Kühn et al., 1995; 
Lakso et al., 1996; Stadtfeld and Graf, 2005). Mice were backcrossed for six 
generations to C57BL/6 mice.
Asxl1fl/fl, Asxl1fl/+, and Asxl1+/+ littermate mice were genotyped by 
PCR  with  primers  Asxl1-F3  (5-CAGCCGTTTTACCACAGTTT-3) 
and Asxl1-R3 (5-AGGGAAAGGGACAGAATGAC-3) using the follow-
ing parameters: 95°C for 4 min, followed by 35 cycles of 95°C for 45 s, 
56°C for 45 s, and 72°C for 1 min, and then 72°C for 5 min. The WT allele 
was detected as a band at 200 bp, whereas the floxed allele was detected as a 
band of 380 bp. Excision after Cre recombination was confirmed by PCR 
with primers to detect a floxed portion of the construct (Asxl1-RecF, 5-ACG-
CCGGCTTAAGTGTACACG-3; and Asxl1-RecR, 5-GACTAAGTT-
GCCGTGGGTGCT-3) using the same parameters as above.
In vivo experiments. Mx1-cre Asxl1fl/fl conditional and Cre Asxl1fl/fl con-
trol mice received five intraperitoneal injections of polyI:polyC every other 
day at a dose of 20 mg/kg of body weight starting at 2 wk after birth. For the 
hematopoietic-specific Vav-cre line, Asxl1fl/flVav-cre+, and Asxl1fl/flVav-cre 
mice were analyzed between 3 and 60 wk of age. BM, spleen, and peripheral 
blood were analyzed by flow cytometry. Formalin-fixed paraffin-embedded 
tissue sections were stained with hematoxylin and eosin (H&E). Peripheral 
blood was smeared on a slide and stained using the Wright-Giemsa staining 
method. Tissue sections and blood smears were evaluated by a hematopathol-
ogist (C.Y. Park) Deletion of the Asxl1 allele and transcript was measured by 
genomic PCR and Western blot analysis.
BM transplantation. Freshly dissected femurs and tibias were isolated from 
Asxl1fl/fl CD45.2+ or Vav-cre+Asxl1fl/fl CD45.2+ mice. BM was flushed with a 
3-cc insulin syringe into PBS supplemented with 3% fetal bovine serum. The 
BM was spun at 0.5 g by centrifugation at 4°C, and RBCs were lysed in am-
monium chloride-potassium bicarbonate lysis buffer for 5 min. After centrifu-
gation, cells were resuspended in PBS plus 3% FBS, passed through a cell 
strainer, and counted. Finally, 0.5 × 106 total BM cells of Asxl1fl/fl CD45.2+ or 
Vav-cre+ Asxl1fl/fl CD45.2+ mice were mixed with 0.5 × 106 WT CD45.1+ 
support BM and transplanted via tail vein injection into lethally irradiated (two 
times 450 cGy) CD45.1+ host mice. Chimerism was measured by FACS in 
peripheral blood at 4 wk after transplant (week 0, pre-polyI:polyC). Chime-
rism was followed via FACS in the peripheral blood every 4 wk (week 0, 4,   
6, 8, 12, and 16 after polyI:polyC injection). Additionally, for each bleeding, 
whole blood cell counts were measured on a blood analyzer, and peripheral 
blood smears were scored. Chimerism in the BM, spleen, and thymus was 
evaluated at 16 wk via animal sacrifice and subsequent FACS analysis. The 
above procedure was also repeated with Asxl1fl/fl CD45.2+, Vav-cre+ Asxl1fl/fl 
CD45.2+, Vav-cre+ Tet2fl/fl CD45.2+, and Vav-cre+ Asxl1fl/fl Tet2fl/fl CD45.2+ 
mice for competitive transplantation of mice with loss of Asxl1, Tet2, or both. 
For noncompetitive transplantation experiments, 106 total BM cells of Asxl1fl/fl 
CD45.2+, littermate Vav-cre+ Asxl1fl/fl CD45.2+, or littermate Mx1-cre+ Asxl1fl/fl 
CD45.2+ mice were injected into lethally irradiated (two times 450 cGy) 
CD45.1+ host mice. Similarly, for LSK transplants, 1,000 FACS-sorted LSK 
cells from secondarily transplanted Asxl1 KO or control mice were trans-
planted into lethally irradiated CD45.1 host mice. Recipient mice were then 
followed until moribund or 80 wk after transplantation.
In vitro colony-forming assays. LSK, CMP, GMP, and MEP cells were 
sorted from the BM of Asxl1fl/fl and littermate Vav-cre+ Asxl1fl/fl mice and 
seeded at a density of 500 cells/replicate for LSK cells and 1,000 cells/repli-
cate for CMP, GMP, and MEP subsets into cytokine-supplemented methyl-
cellulose medium (Methocult M3434; STEMCELL Technologies). Colonies 
propagated in culture were scored at day 7. Representative colonies were iso-
lated from the plate for cytospins. Remaining cells were resuspended and 
Asxl1-binding sites revealed enrichment in known binding sites 
of the Ets family of transcription factors. The significant overlap 
between genome-wide binding of Asxl1 and Ets family mem-
bers is critically supportive of the importance of Asxl1 in hema-
topoiesis as the Ets family of transcription factors are very well 
understood to play a key role in the growth, survival, differentia-
tion, and activation of hematopoietic cells (Mizuki et al., 2003; 
Vangala et al., 2003; Koschmieder et al., 2005; Steidl et al., 2006; 
Choi et al., 2008). Deletion, mutation, and translocation of ETS 
family  members  are  well-described  in  myeloid  malignancies 
(Gilliland, 2001), including ETV6 mutations/translocations in 
MDS and chronic myelomonocytic leukemia (Haferlach et al., 
2012) and loss-of-function mutations of PU.1 in AML (Mueller 
et al., 2002). Moreover, common oncogenic events seen in pa-
tients with myeloid malignancies have been demonstrated to 
transform myeloid cells through suppression of expression of   
key Ets members. For example, FLT3-ITD mutations and the 
AML1-ETO (t(8;21)) fusion oncoprotein have been shown 
to suppress PU.1 expression and function (Mizuki et al., 2003; 
Vangala et al., 2003). In addition, down-regulation of PU.1 ex-
pression results in impaired myeloid differentiation (Rosenbauer 
et al., 2004; Steidl et al., 2006). Further work to understand the 
involvement of individual Ets family members and/or a shared 
transcriptional  program  between Asxl1  loss  and  Ets  family 
member loss (Steidl et al., 2006) in the pathogenesis of ASXL1 
mutant myeloid malignancy will be critical.
Collectively, our experiments reveal that deletion of Asxl1 
results in craniofacial and skeletal developmental abnormalities 
and mice with hematopoietic-specific Asxl1 loss developed 
hallmark features of MDS, including progressive ineffective 
hematopoiesis, impaired myeloid differentiation, multilineage 
dysplasia, and increased apoptosis and altered cell cycle regu-
lation of HSPCs. Given the paucity of mouse models of human 
MDS based on known, recurrent MDS disease alleles, we be-
lieve the development of a genetically accurate model of 
MDS will inform subsequent studies aimed to elucidate the 
molecular basis for MDS and to develop novel therapies for 
MDS patients.
MATERIALS AND METHODS
Animals. All animals were housed at New York University School of Med-
icine or at Memorial Sloan-Kettering Cancer Center. All animal procedures 
were conducted in accordance with the Guidelines for the Care and Use of 
Laboratory Animals and were approved by the Institutional Animal Care and 
Use Committees at New York University School of Medicine and Memorial 
Sloan-Kettering Cancer Center.
Generation of Asxl1-deficient mice. The Asxl1 allele was deleted by tar-
geting exons 5–10. Two LoxP sites flanking exon 5–10 and an Frt-flanked 
neomycin selection cassette were inserted in the upstream intron (Fig. 1 A). 
10 µg of the targeting vector was linearized by NotI and then transfected by 
electroporation of BAC-BA1 (C57BL/6 × 129/SvEv) hybrid ES cells. After 
selection with G418 antibiotic, surviving clones were expanded for PCR 
analysis to identify recombinant ES clones. Secondary confirmation of posi-
tive clones identified by PCR was performed by Southern blotting analysis. 
DNA was digested with BamHI and electrophoretically separated on a 0.8% 
agarose gel. After transfer to a nylon membrane, the digested DNA was hy-
bridized with a probe targeted against the 3 or 5 external region. DNA 
from C57BL/6 (B6), 129/SvEv (129), and BA1 (C57BL/6 × 129/SvEv; JEM Vol. 210, No. 12 
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Sequenced reads were aligned to the reference genomes (mm9) using 
bowtie with maximum two mismatches, keeping only uniquely mapping 
reads. Peak calling was performed using MACS1.4 with the following op-
tions: -p 1e-7,–nomodel True,–shiftsize 100,–keep-dup 1. Peaks were as-
signed to genes using bedtools. We considered Asxl1-bound genes to be any 
mouse RefSeq entry containing a peak overlapping the gene or 2 kb upstream 
of the TSS. ChIP-Seq read profile and heat map densities were generated 
using  genomic  tools.  Mouse  RefSeq  and  CpG  island  annotations  were 
downloaded from the UCSC Genome Bioinformatics Table Browser.
Skeletal preparations. Skeletal preparations were performed as described 
previously (de Pontual et al., 2011).
Online supplemental material. Table S1, included as a separate PDF file, 
shows differentially expressed transcripts between 1-yr-old Mx1-cre Asxl1fl/fl 
and Asxl1fl/fl LSK cells by RNA sequencing. Table S2, included as a separate 
PDF file, shows differentially expressed transcripts between 1-yr-old Mx1-cre 
Asxl1fl/fl and Asxl1fl/fl MPs by RNA sequencing. Table S3, included as a sepa-
rate PDF file, shows differentially expressed genes in LSK cells from 6-wk-
old Mx1-cre Asxl1fl/fl, Mx1-cre Tet2fl/fl, and Mx1-cre Asxl1fl/fl Tet2fl/fl. Table S4, 
included as a separate PDF file, shows regions with significant Asxl1 binding 
by anti-Asxl1 ChIP-Seq. Table S5, included as a separate PDF file, shows 
genes with significant Asxl1 binding ±2 kb from the TSS as determined by 
anti-Asxl1 ChIP-Seq. Online supplemental material is available at http://
www.jem.org/cgi/content/full/jem.20131141/DC1.
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